Mirta ML Sousa
Dr. Mirta Mittelstedt Leal de Sousa is a researcher at the Norwegian University of Science and Technology (NTNU), specializing in proteomics and neurodegenerative diseases. She earned her PhD in Molecular Medicine in 2012 for her work on DNA repair and biochemistry in cancer research. During her postdoctoral training, Dr. Sousa advanced her expertise in quantitative targeted mass spectrometry at the Lawrence Berkeley National Laboratory and the Joint BioEnergy Institute (JBEI) in California, USA.
Her current research focuses on molecular mechanisms and therapeutic development for rare neurodegenerative disorders, particularly CLN3 Batten disease. She collaborates with Professor Magnar Bjørås’s group at NTNU, applying patient-derived retinal, brain, and neuromuscular junction organoids to develop precision medicine approaches for CLN3 disease.
In addition to her academic work, Dr. Sousa is a co-founder of Zenit Science AS and Nocteva AS, contributing to translational research and innovation in biomedical science.
Abstracts this author is presenting: